Jade Biosciences, Inc. — Director's Dealing 2021

Dec 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-12-14

Reporting Person: NIVEN RALPH (Chief Development Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-14	Stock Option (Right to Buy)	$10.61	A	65433	Acquired	2031-12-13	Common Stock (65433)	Direct

Footnotes

F1: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on January 14, 2022.